Patents Assigned to ASCENDIS PHARMA GROWTH DISORDERS A/S
-
Patent number: 11564974Abstract: The present invention relates to a combination of a CNP agonist and at least one further biologically active moiety or drug for use in a method for the treatment or prevention of disorders that benefit from stimulating growth, pharmaceutical compositions comprising at least one CNP agonist, preferably controlled-release CNP agonist, wherein the pharmaceutical composition comprises at least one further biologically active moiety or drug, to using these pharmaceutical compositions as a medicament, to their use in the treatment of disorders that benefit from stimulating growth and to methods of preventing or treating a patient having a disorder that benefits from stimulating growth.Type: GrantFiled: September 28, 2017Date of Patent: January 31, 2023Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Lars Holten-Andersen, Vibeke Miller Breinholt, Kennett Sprogøe
-
Publication number: 20220296682Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.Type: ApplicationFiled: November 15, 2021Publication date: September 22, 2022Applicant: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
-
Patent number: 11413351Abstract: The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.Type: GrantFiled: January 5, 2017Date of Patent: August 16, 2022Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
-
Patent number: 11389510Abstract: The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC50 that is at least 20-fold higher than the EC50 of the corresponding free CNP agonist and which released CNP agonist has an EC50 that is at most 3-fold higher than the EC50 of the corresponding free CNP agonist; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.Type: GrantFiled: January 5, 2017Date of Patent: July 19, 2022Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Kennett Sprogøe, Harald Rau, Felix Cleemann, Ulrich Hersel, Caroline Elisabeth Rasmussen
-
Patent number: 11389511Abstract: The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment.Type: GrantFiled: January 5, 2017Date of Patent: July 19, 2022Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Kennett Sprogøe, Harald Rau, Felix Cleemann, Ulrich Hersel, Caroline Elisabeth Rasmussen
-
Patent number: 11311604Abstract: The present invention relates to a controlled-release CNP agonist having low NPR-C affinity; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.Type: GrantFiled: January 5, 2017Date of Patent: April 26, 2022Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Harald Rau, Ulrich Hersel, Kennett Sprogøe, Frank Faltinger, Thomas Wegge, Felix Cleemann
-
Patent number: 11224661Abstract: The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.Type: GrantFiled: January 5, 2017Date of Patent: January 18, 2022Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Kennett Sprogøe, Harald Rau, Ana Bernhard, Ulrich Hersel, Felix Cleenmann, Thomas Wegge
-
Patent number: 11154593Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.Type: GrantFiled: February 24, 2021Date of Patent: October 26, 2021Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
-
Publication number: 20210177942Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.Type: ApplicationFiled: February 24, 2021Publication date: June 17, 2021Applicant: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
-
Publication number: 20210069339Abstract: The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.Type: ApplicationFiled: August 13, 2020Publication date: March 11, 2021Applicant: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Kennett Sprogøe, Ulrich Hersel, Harald Rau, Thomas Wegge, Frank Faltinger, Felix Cleemann, Nora Kaluza, Ana Bernhard, Annette Buba, Tom Woods
-
Patent number: 10835578Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.Type: GrantFiled: January 5, 2017Date of Patent: November 17, 2020Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
-
Publication number: 20200276270Abstract: The present invention relates to a combination of a CNP agonist and at least one further biologically active moiety or drug for use in a method for the treatment or prevention of disorders that benefit from stimulating growth, pharmaceutical compositions comprising at least one CNP agonist, preferably controlled-release CNP agonist, wherein the pharmaceutical composition comprises at least one further biologically active moiety or drug, to using these pharmaceutical compositions as a medicament, to their use in the treatment of disorders that benefit from stimulating growth and to methods of preventing or treating a patient having a disorder that benefits from stimulating growth.Type: ApplicationFiled: September 28, 2017Publication date: September 3, 2020Applicant: Ascendis Pharma Growth Disorders A/SInventors: Lars Holten-Andersen, Vibeke Miller Breinholt, Kennett Sprogøe
-
Publication number: 20190255183Abstract: The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.Type: ApplicationFiled: February 6, 2019Publication date: August 22, 2019Applicant: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Kennett Sprogøe, Ulrich Hersel, Harald Rau, Thomas Wegge, Frank Faltinger, Felix Cleemann, Nora Kaluza, Ana Bernhard, Annette Buba, Tom Woods
-
Publication number: 20190015481Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.Type: ApplicationFiled: January 5, 2017Publication date: January 17, 2019Applicant: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
-
Publication number: 20190008977Abstract: The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.Type: ApplicationFiled: January 5, 2017Publication date: January 10, 2019Applicant: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen